Willis-Knighton Medical Center in Shreveport is one of 120 sites nationwide that will participate in a clinical trial for Regeneron’s COVID monoclonal antibody treatment.
Children’s Health Services Director Dr. Joseph Bocchini said they need COVID-positive participants and know early results for people with comorbidities show the treatment reduces the rate of hospitalization by 70 percent and the length of symptoms by four days.
The objective is to enroll enough people to study the effects of Regeneron on pregnant women and children, but Bocchini said with COVID numbers declining it will be a challenge.
“It is worth it for those individuals who are infected because it gives them an opportunity to participate if they desire,” said Bocchini.
Estimates show at our current rate of vaccination we could hit herd immunity by late summer, but Bocchini said even after that there will still be a need for COVID treatments.
“All of the vaccines that we have are very effective, however they are not 100 percent effective so it is possible that there will continue to be some breakthrough cases,” said Bocchini who added the treatment will also be useful for people who refuse to take the vaccine.
Those participating in the 29 day study will receive a single dose of Regeneron at the WK COVID Research Infusion Center in Shreveport. Participants will be monitored at home and tested by healthcare workers. Those interested should call 318-455-9730 or go to www.wkhs.com/clinical-trial.
Comments